Skip to main content

Table 2 Serum levels of SP-A, SP-D, and KL-6 at baseline, 3, and 6 months

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

 

Baseline

3 months

6 months

Stable group

 SP-A (ng/mL)

60.3 (42.6–76.1)

53.1 (36.6–68.0) *

49.2 (37.1–71.7) *

 SP-D (ng/mL)

241 (177–357)

194 (149–296)

195 (128–263)

 KL-6 (U/mL)

885 (595–1618)

775 (581–1154) *

738 (503–1213) *#

Progression group

 SP-A (ng/mL)

56.6 (40.6–96.7)

67.0 (46.8–111.8) *

69.3 (42.7–117.8) *

 SP-D (ng/mL)

246 (166–350)

261 (180–323)

224 (192–353)

 KL-6 (U/mL)

901 (732–1337)

1195 (653–1821)

1237 (748–1570) #

  1. Data are expressed as medians (interquartile range).
  2. *: Bonferroni-corrected p < 0.05 baseline vs. 3 or 6 months. #: p < 0.05 stable group vs. progression group. SP surfactant protein; KL-6 Krebs von den Lungen-6
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us